Lilly Asia Ventures
Overview
Lilly Asia Ventures is a venture capital firm founded in 2008 that invests in the life sciences and healthcare sectors, including biopharmaceuticals, medical devices, and diagnostics, primarily in Asia and the United States.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Abogen Biosciences | Aug 2021 | Series C | Lead |
| RemeGen | Nov 2020 | IPO | Co-investor |
| MediTrust Health | Aug 2021 | Series C | Co-investor |
| Insilico Medicine | Jun 2021 | Series C | Co-investor |
| Alumis Inc | Mar 2024 | Series C | Co-investor |
For institutional investors. Book with your work email.
Key People
Stella Shi
Founder, CEO
Lilian Wan
Principal
John Ma
Non-Executive Board Director
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Lilly Asia Ventures based?
Lilly Asia Ventures is headquartered in Shanghai, China.
When was Lilly Asia Ventures founded?
Lilly Asia Ventures was founded in 2008.
How many portfolio companies does Lilly Asia Ventures have?
Lilly Asia Ventures has 49 portfolio companies in Caplight's dataset.
What are some companies in Lilly Asia Ventures's portfolio?
Portfolio companies visible on Caplight include Abogen Biosciences, RemeGen, MediTrust Health, Insilico Medicine, Alumis Inc.
What was Lilly Asia Ventures's most recent investment shown here?
Lilly Asia Ventures's most recent investment in this portfolio sample was in Alumis Inc in 2024.
What sectors does Lilly Asia Ventures focus on?
Lilly Asia Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, FinTech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Frontier & Industrial Tech.
What company stages does Lilly Asia Ventures focus on?
Lilly Asia Ventures typically invests at the Mid stage.
What is Lilly Asia Ventures's AUM?
Lilly Asia Ventures's assets under management are estimated between $4.5B and $4.5B.